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Sheikh K, Paulin GA, Svenningsen S, Kirby M, Paterson NA,
McCormack DG, Parraga G. Pulmonary ventilation defects in older
never-smokers. J Appl Physiol 117: 297–306, 2014. First published
June 5, 2014; doi:10.1152/japplphysiol.00046.2014.—Hyperpolar-
ized 3He MRI previously revealed spatially persistent ventilation
defects in healthy, older compared with healthy, younger never-
smokers. To understand better the physiological consequences and
potential relevance of 3He MRI ventilation defects, we evaluated
3He-MRI ventilation-defect percent (VDP) and the effect of deep
inspiration (DI) and salbutamol on VDP in older never-smokers. To
identify the potential determinants of ventilation defects in these
subjects, we evaluated dyspnea, pulmonary function, and cardiopul-
monary exercise test (CPET) measurements, as well as occupational
and second-hand smoke exposure. Fifty-two never-smokers (71  6
yr) with no history of chronic respiratory disease were evaluated.
During a single visit, pulmonary function tests, CPET, and 3He MRI
were performed and the Burden of Obstructive Lung Disease ques-
tionnaire administered. For eight of 52 subjects, there was spirometry
evidence of airflow limitation (Global Initiative for Chronic Obstruc-
tive Lung Disease-Unclassified, I, and II), and occupational exposure
was reported in 13 of 52 subjects. In 13 of 52 (25%) subjects, there
were no ventilation defects and in 39 of 52 (75%) subjects, ventilation
defects were observed. For those subjects with ventilation defects, six
of 39 showed a VDP response to DI/salbutamol. Ventilation hetero-
geneity and VDP were significantly greater, and forced expiratory
volume in 1 s (FEV1)/forced vital capacity was significantly lower
(P  0.05) for subjects with ventilation defects with a response to
DI/salbutamol than subjects with ventilation defects without a re-
sponse to DI/salbutamol and subjects without ventilation defects. In a
step-wise, forward multivariate model, FEV1, inspiratory capacity,
and airway resistance significantly predicted VDP (R2  0.45, P 
0.001). In conclusion, most never-smokers had normal spirometry and
peripheral ventilation defects not reversed by DI/salbutamol; such
ventilation defects were likely related to irreversible airway narrow-
ing/collapse but not to dyspnea and decreased exercise capacity.
bronchodilation; cardiopulmonary exercise testing; deep inspiration;
pulmonary aging; 3He MRI
PULMONARY AGING IS CONCOMITANT with changes in elastic recoil
(10, 42, 43), chest-wall compliance (10, 43), and respiratory
muscle strength (8, 21). In concert with these physiological
changes, functional residual capacity (FRC), residual volume
(RV), and airway resistance (Raw) also increase (21), whereas the
forced expiratory volume in 1 s (FEV1), forced vital capacity
(FVC) (9), and inspiratory capacity (IC) decrease (35).
Healthy, older adults may experience breathlessness during
everyday activities (1, 17, 19, 30, 41), and this is related to
mortality risk (1, 19, 41). In addition, in older adults, cardio-
pulmonary exercise test (CPET) measurements (3) correlate
more strongly with overall health status than do measurements
of resting lung function (3a, 12, 33). Moreover, CPET mea-
surements show that in “normal,” healthy aging, there is lower
exercise-related oxygen uptake (VO2), as well as greater min-
ute ventilation (VE) and increased respiratory exchange ratio
(RER) (16, 23, 24). Recent studies have also shown that during
exercise, significant ventilatory impairment is possible without
increased dyspnea or premature exercise limitation (13).
The role of occupational and second-hand tobacco smoke
exposure is important to acknowledge and understand in both
normal and accelerated lung aging. In this context, the Burden
of Obstructive Lung Disease (BOLD) study (5) showed that in
never-smokers, the prevalence of airflow limitation consistent
with chronic obstructive pulmonary disease (COPD) was as
high as 30%. The BOLD study also revealed the critical
relationships in never-smokers among airflow limitation and
age, history of occupational exposure, and childhood respira-
tory disease (28).
3He ventilation MRI provides high-resolution, noninvasive
measurements of lung function (27, 37) and identifies those
regions of the lung that participate in ventilation and those that
do not (27, 36). In healthy, young subjects, a single inhalation
of hyperpolarized 3He gas results in homogeneous lung filling,
but in older never-smokers, characteristic “focal” ventilation
defects are observed, corresponding to poorly ventilated lung
regions (36, 37). In older never-smokers, ventilation defects
are commonly observed on the lung periphery and the depen-
dent lung regions, and this is in contrast with COPD and
asthma, where numerous and large defects are heterogeneously
distributed throughout the lung (6, 27, 37).
The finding of spatially and temporally persistent 3He MRI
ventilation defects in older never-smokers with normal spirom-
etry (36, 37) raises questions about the physiological meaning
of ventilation defects in all subjects. For example, as shown
previously, 3He MRI ventilation abnormalities induced by
methacholine challenge in young, healthy volunteers were
reversed by deep inspiration (DI) (44). In young asthmatics,
salbutamol inhalation reduced ventilation defects observed
with 3He MRI after methacholine challenge (40), but the effect
of DI was not investigated. Raw measurements determined that
asthmatic subjects cannot maximally dilate their airways and that
the dilation that does occur after DI constricts back to baseline
much faster than in healthy subjects (22). This suggested that in
asthma, ventilation defects were related to salbutamol-responsive
airway abnormalities, whereas in healthy volunteers, ventilation
defects may reflect normal airway smooth muscle behavior that is
reversible using DI.
We hypothesized that in older never-smokers, narrowed or
collapsed airways were responsible for the persistent ventila-
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tion defects observed, and these would be responsive to and
improve following DI. To test this hypothesis, we evaluated the
effect of both DI and salbutamol on 3He ventilation defects in
a relatively large group of older never-smokers with no history
of respiratory disease. We also evaluated the relationship of
ventilation defects with occupational exposures, pulmonary
function, and CPET measurements.
MATERIALS AND METHODS
Study subjects and logistics. All subjects provided written, in-
formed consent to a study protocol approved by a Local Research
Ethics Board and Health Canada. Subjects were enrolled between the
ages of 60 and 90 yr with a smoking history of 0.5 pack-years and
no history of chronic respiratory or cardiovascular disease. After
providing consent, all subjects made a single, 2- to 3-h visit and
underwent the following evaluations in the same order: 1) BOLD
occupational questionnaire (5), 2) spirometry, 3) plethysmography
and the diffusing capacity of carbon monoxide (DLCO), 4) CPET,
including dyspnea score, and 5) MRI. Pulmonary function tests were
completed in 45 min, followed by CPET, which was completed in
10–15 min. MRI was performed following CPET, and for subjects
who did not have ventilation defects and those with defects that
responded to DI, MRI was completed within 10–15 min. For subjects
who were administered salbutamol, MRI was performed 25–30 min
post-salbutamol inhalation.
Questionnaire. All subjects completed the BOLD occupational
questionnaire (5) with exposures defined as described previously (28),
including: 1) organic dust (farming; flour, feed, or grain milling; and
cotton or jute processing), 2) inorganic dust (working with asbestos;
hard-rock mining; coal mining; sandblasting; and foundry or steel
milling), and 3) irritant gases (welding; firefighting; and chemical or
plastics manufacturing). We also queried subjects directly about
spousal and/or life-partner smoking history and recorded potential
household second-hand smoke exposure.
Pulmonary function and CPETs. Spirometry was performed using
an EasyOne spirometer (ndd Medizintechnik, Zurich, Switzerland),
according to American Thoracic Society (ATS) guidelines (31). Body
plethysmography was performed for the measurement of lung vol-
umes, and DLCO was measured using the gas analyzer (MedGraphics,
St. Paul, MN). IC, defined as the volume change recorded at the
mouth when taking a slow, full inspiration from a position of passive
end-expiration, was measured using body plethysmography (31), as
was Raw, defined as the pressure difference/unit flow. Post-DI pul-
monary function tests were not performed, but for subjects adminis-
tered salbutamol, FEV1 and FVC were recorded, 35–40 min postin-
halation and upon completion of MRI.
After completion of pulmonary function tests, all subjects per-
formed CPET using a cycle ergometer (Ultima PFX; MedGraphics),
according to ATS guidelines (3a), with a 2-min warm-up with no
resistance, followed by a 20-W incremental increase in work rate.
Subjects were required to pedal at a frequency of 60 rpm with
increasing work rate until the ventilatory anaerobic threshold was
reached. Ventilatory anaerobic threshold was defined as the time when
CO2 production increased disproportionately in relation to VO2. The
ventilatory anaerobic threshold was determined by onboard software
for the CPET unit, which used an iterative regression and analysis of
slope. Subjects continued exercise until fatigue was reported. VO2,
RER, work rate (i.e., power), as well as VE were measured at rest, at
the ventilatory anaerobic threshold, and when maximum pulmonary
VO2 (VO2max) was reached. The time taken to reach VO2max was
also recorded. CPET measurements, including VO2, power, and VE,
were adjusted for age, sex, and height using percent-predicted values
reported previously (11, 16, 24). Borg dyspnea and leg discomfort
scales were used before and after exercise.
Image acquisition. MRI was performed after completion of all
pulmonary function and CPETs on a 3.0 Tesla MR750 (GE Health-
care, Milwaukee, WI) system, as described previously (37), using a
whole-body gradient set with a maximum gradient amplitude of 1.94
G/cm and a single-channel, rigid elliptical transmit/receive chest coil
(Rapid Biomedical GmbH, Rimpar, Germany). For both 1H and 3He
MRI, subjects were instructed to inhale a gas mixture from a 1-liter
Tedlar bag (Jensen Inert Products, Coral Springs, FL) from FRC, and
image acquisition was performed during a 16-s breath-hold. Coronal
(anatomical) 1H MRI was performed using the whole-body radiofre-
quency coil and 1H fast-spoiled, gradient-recalled echo sequence
using a partial echo [16 s total data acquisition; repetition time
(TR)/echo time (TE)/flip angle  4.7 ms/1.2 ms/30°, field of view
(FOV)  40  40 cm, bandwidth  24.4 kHz, matrix  128  80,
15–17 slices, 15 mm slice thickness, zero gap], as described previ-
ously (37). 3He MRI static ventilation images were acquired using a
fast-gradient echo method using a partial echo (14 s total data
acquisition; TR/TE/flip angle  4.3 ms/1.4 ms/7°, FOV  40  40
cm, bandwidth  48.8 kHz, matrix  128  80, 15–17 slices, 15 mm
slice thickness, zero gap).
Immediately after image acquisition at the scanner, while the
subject was still in position, 3He static ventilation images were
qualitatively evaluated for ventilation abnormalities by a single,
trained observer. If 3He gas were homogeneously distributed through-
out the lung, and there were no visible ventilation defects, then the
subjects were classified as belonging to the no-defect group, and the
session was deemed complete. In contrast, if 3He gas were heteroge-
neously distributed throughout the lung and/or there were visually
obvious ventilation defects, then the subject was classified as having
ventilation defect(s). Upon qualitative inspection, subjects with visu-
ally obvious ventilation defects were instructed to perform DI. They
were instructed to sit up while remaining on the scanner bed and to
take four deep breaths in through their nose and out through their
mouth. Imaging was performed immediately following DI. If defects
persisted following DI, then the subject inhaled four puffs (400 g) of
salbutamol while seated upright, and 25 min later, imaging was
performed on a final occasion.
Image analysis. Based on visual inspection at the scanner, subjects
were classified as: 1) no defects—those subjects without visually
obvious ventilation defects, 2) subjects with ventilation defects that
responded to DI or salbutamol, and 3) subjects with ventilation defects
that did not respond to DI or salbutamol. 3He MRI semiautomated
segmentation was performed, as described previously (25), to gener-
ate ventilation-defect percent (VDP)—the ventilation defect volume
(VDV) normalized to 1H MRI thoracic cavity volume. Briefly, 3He
static ventilation images were segmented using a k-means approach
that classified voxel-intensity values into five clusters, ranging from
signal void [cluster 1 (C1) or VDV] and hypointense [cluster 2 (C2)]
to hyperintense signal [cluster 5 (C5)], therefore generating a gas
distribution cluster map. For delineation of the ventilation-defect
boundaries, a seeded, region-growing algorithm was used to segment
the 1H MRI thoracic cavity for registration to the cluster map, as
described previously (25).
Ventilation heterogeneity was estimated, according to a previously
described method (44), using the coefficient of variation (COV). A
local COV, rather than a global COV, was generated (44) to ensure
that local ventilation heterogeneity was not ignored. Briefly, for each
voxel in a region of interest (ROI), a local ventilation heterogeneity
value was calculated by computing the COV of the signal intensity in
a 5  5 voxel neighborhood, which corresponded to a 244-mm2 area
centered on that voxel. To ensure that the 5  5 voxel neighborhood
did not include voxels that were outside of the lungs, a signal-to-noise
threshold of five was established. For example, any voxels that were
in a neighborhood with an overall signal-to-noise ratio (SNR) of less
than five were excluded from the COV computation. COV of the lung
was calculated for each subject as in Eq. 1
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N
where i is the SD of the signal intensity of the 5  5 voxel
neighborhood, i is the mean signal intensity of the 5  5 voxel
neighborhood, and N is the number of ventilation ROIs in the lung.
The ventilated lung ROI was defined as gas distribution cluster map
C2–C5.
We also measured regional differences in VDP for the center nine,
15 mm-thick slices using several different measurements, as shown in
Fig. 1. The VDP gradient in the posterior-anterior (PA) direction was
defined as the slope of the line that described the change in VDP from
the most posterior slice in centimeters over the nine central slices
(with a slice thickness of 15 mm each). The center nine slices were
used to ensure that the static ventilation slices across subjects had
adequate SNRs (i.e., SNR  10) for VDP calculations, as well as to
maintain an equal number of slices among all subjects. To calculate
the gradient in the superior-inferior (SI) direction, the center nine
coronal slices were reformatted into 15-mm axial slices. The VDP SI
gradient was defined as the slope of the line that described the change
in VDP over the axial SI slices. In addition, the VDP difference
between the most posterior and anterior slices (VDP 	PA) was
calculated, as was the VDP difference between the most superior and
inferior slices (VDP 	SI) of the central nine slices. The VDP located
on the peripheral boundary of the lung (relative peripheral VDP) was
estimated as the ratio of the VDV for the outermost 10 voxels of each
slice (not including boundary voxels, defined as SNR  2) to the 1H
MRI thoracic-cavity volume. The proportion of ventilation defects
located on the peripheral boundary was quantified as the ratio of
peripheral lung VDV to whole-lung VDV (i.e., VDVPer/VDVWL).
Statistical analysis. ANOVA, multivariate regression, and post hoc
analysis, using the Holm Bonferroni correction (45), were performed
using SPSS 20.0 software (IBM, Armonk, NY). Paired sample t-tests
were performed to determine the differences in VDP 	PA and VDP
	SI using SPSS 20.0. We used the National Health and Nutrition
Examination Survey III reference standards (14) for percent-predicted
values. Univariate relationships were determined using regression (r2)
and Pearson correlation coefficients (r) for all subjects with GraphPad
Prism V.6.00 (GraphPad Software, La Jolla, CA). Step-wise, multi-
variate regression was used to identify the predictors of VDP. The
variables considered for modeling were chosen based on statistically
significant, univariate relationships with VDP. Results were consid-
ered statistically significant when the probability of making a type I
error was 5% (P  0.05).
RESULTS
Subject data. As summarized in Table 1 (and a detailed
subject listing in Table 2), 52 never-smokers (71  6 yr)
completed all measurements during a single visit. In total, there
were 13 of 52 (25%) subjects without 3He MRI ventilation
defects and 39 of 52 (75%) with ventilation defects. Of those
subjects with ventilation defects, six (of 39, 15%) showed a
VDP response (i.e., visually obvious and quantitative decrease
in VDP) to DI (n  4) or salbutamol (n  2).
Figure 2 shows 3He MRI coronal slices at baseline, post-DI,
and post-salbutamol for four representative subjects. For the
subject shown without ventilation defects, there was homoge-
neous signal intensity over the entire lung with no obvious
ventilation defects in the center MR slice or any of the
anterior-to-posterior slices. For two representative subjects that
showed an imaging response to DI or salbutamol, there were
ventilation defects peripherally located in the central and pos-
terior slices that resolved in response to DI or bronchodilation.
For the representative subject with ventilation defects that did
not appear to respond to DI or salbutamol, a number of small
peripheral ventilation defects remained spatially persistent
post-DI and 25 min after salbutamol inhalation.
For the three comparator groups (Table 1), there was no
significant difference for age, sex, or body mass index. How-
ever, there was a significant difference for FEV1/FVC (P 
0.004), VDP, 3He COV, VDP 	PA, and PA gradient (P 
0.001), as well as relative peripheral VDP (P  0.001). There
was no significant difference for any CPET or other pulmonary
function measurements for the three subgroups. Post hoc anal-
ysis showed that the imaging responder group had significantly
lower FEV1/FVC and significantly higher VDP, 3He COV, PA
	VDP, PA VDP gradient, and relative peripheral VDP than the
no-defect and no-imaging-response groups. Figure 3 shows
scatter plots for VDP, relative peripheral VDP, VDP 	PA,
VDP 	SI, PA VDP gradient, SI VDP gradient, and 3He COV.
Table 2 shows that 13 subjects reported significant exposure,
10 of whom (77%) had ventilation defects. Of those 10 sub-
jects, three showed an imaging response to DI or salbutamol.
Table 2 also shows that eight never-smokers had spirometry
evidence of airway obstruction (47) [Global Initiative for
Chronic Obstructive Lung Disease (GOLD)–Unclassified (n 
2), GOLD I (n  4), GOLD II (n  2)]. Five of these eight
subjects reported second-hand smoke or occupational expo-
sures, and two subjects responded to salbutamol. In addition,
10 never-smokers had 0.70  FEV1/FVC  0.73, where the
0.73 threshold was used to compensate for the variability in
FEV1 and FVC (20, 29). The eight never-smokers with spi-
rometry evidence of COPD had significantly greater VDP
(5.5 3.1%, P 0.001) than the never-smokers with (VDP
2.5  1.2%) or without (VDP  1.6  0.7%) ventilation
defects. When the subjects with spirometry evidence of COPD
(n  8) were removed in a sub-analysis, only VDP remained
significantly different across all three subgroups (P  0.03).
Post hoc analysis showed that the no-imaging-response group
had greater baseline VDP than the no-defect group but was not
significantly different from the imaging-response group.
Pre- and post-DI/salbutamol analysis. Table 3 shows a
subject listing for pre- and post-salbutamol FEV1, VDP, and
3He COV for all subjects administered salbutamol (n  35).
Three subgroups were identified for those subjects adminis-
Fig. 1. Schematic for regional evaluation of 3He MRI ventilation-defect
percent (VDP). The central coronal static ventilation image slices (9 15 mm)
were evaluated. The lung was also divided into 15-mm slices in the axial
direction. The VDP 	SI was defined as the difference between the most
superior slice and the most inferior slice. The VDP 	PA was defined as the
difference between the most posterior slice and the most anterior slice.
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tered salbutamol: imaging responders, FEV1 responders, and
nonresponders. Twenty-eight of 35 subjects did not show an
imaging response or a FEV1 response to salbutamol. There
were five subjects who responded to salbutamol (	FEV1 
200 ml) but did not have an imaging (VDP or C1) response to
salbutamol. In addition, for these five subjects, there was no
significant change in any of ventilation C2–C5 or any combi-
nation of ventilation clusters (i.e., C1 
 C2) post-salbutamol.
It is worth noting that one of the five FEV1 responders reported
30 yr of occupational exposure working in the steel mill
industry (S63), whereas two were lifelong farmers (S25 and
S59). Finally, for those subjects administered salbutamol, there
were no relationships for the change in FEV1 post-salbutamol
with change in VDP (r2  0.04, P  0.50) or change in 3He
COV (r2  0.08, P  0.10).
Table 4 shows VDP and 3He COV measurements for all
three time points for imaging responders (DI or salbutamol
responders). There were no statistically significant differences
in 3He COV or VDP across time points for the imaging
responders.
Relationships between imaging and other measurements.
Table 5 shows the results of a forward, step-wise multivariate
regression model using 3He VDP as the dependent variable and
all significant pulmonary function test measurements (obtained
from the univariate analysis) as the independent variables.
FEV1%pred, IC%pred, and Raw%pred were shown to predict
45% of the variability in VDP (P  0.001), with FEV1%pred
making the greatest contribution. The univariate relationships
are shown in Fig. 4, including FEV1%pred (r2  0.29, P 
0.0001), Raw%pred (r2 0.29, P 0.0001), and IC%pred (r2
0.17, P  0.003). There were no statistically significant
relationships for VDP with CPET, dyspnea, or occupational-
exposure measurements. It is important to note that three
subjects had VDP  3 SD of the mean, and when these data
were removed from the regression analysis, FEV1%pred
(r2  0.13, P  0.009) and IC%pred (r2  0.17, P  0.003)
Table 1. Baseline subject demographic and other measurements
Ventilation Defects (n  39) Significance of Difference
No Defects Imaging Response No Imaging Response (P value)*
(n  13) (n  6) (n  33) ND-IR-NIR
Demographics
Age, yr (SD) 71 (8) 72 (4) 71 (6) 0.90
Men, n 6 3 12
BMI, kg/m2 ([plusmn]SD) 26 (4) 27 (3) 26 (3) 0.90
Occupational exposures
Organic dust, n 3 1 4
Inorganic dust, n 0 2 2
Irritant gases, n 0 0 1
Pulmonary function
FEV1%pred (SD) 113 (11) 93 (29) 106 (20) 0.09
FVC%pred (SD) 107 (15) 96 (26) 103 (17) 0.40
FEV1/FVC, % (SD) 80 (5) 71 (4)† 77 (5) 0.004
FRC%pred (SD) 105 (24) 114 (15) 107 (17) 0.60
IC%pred (SD) 112 (20) 94 (26) 106 (19) 0.20
RV/TLC, % (SD) 41 (7) 43 (15) 41 (7) 0.50
DLCO%pred (SD) 96 (7) 75 (13) 92 (19) 0.07
Raw%pred (SD) 71 (25) 100 (82) 72 (31) 0.20
CPET
VO2max%pred (SD) 83 (18) 86 (11) 87 (19) 0.80
RER (SD) 1.17 (0.15) 1.19 (0.11) 1.21 (0.12) 0.90
Power%pred (SD) 126 (38) 118 (9) 121 (31) 0.70
VEmax%pred (SD) 50 (17) 54 (19) 51 (16) 0.90
Postexercise dyspnea (SD) 2.1 (1.4) 2.0 (1.0) 2.3 (1.6) 0.80
Postexercise leg discomfort (SD) 11.5 (2.4) 11.0 (3.7) 10.9 (3.3) 0.90
Time to VO2max, s (SD) 478 (89) 532 (111) 494 (82) 0.50
MRI
VDP, % (SD) 1.6 (0.7) 5.8 (3.8)† 2.6 (1.2) 0.001
3He COV (SD) 0.19 (0.01) 0.24 (0.04)† 0.21 (0.02) 0.001
VDP 	PA, % (SD) 0.7 (2.7) 11.2 (13.5)† 1.5 (4.0) 0.001
PA VDP gradient, %/cm (SD) 0.02 (0.17) 0.69 (0.93)† 0.05 (0.21) 0.001
VDP 	SI, % (SD) 1.9 (1.3) 3.4 (9.6) 2.8 (2.3) 0.67
SI VDP gradient, %/cm (SD) 0.14 (0.1) 0.26 (0.72) 0.21 (0.17) 0.67
Relative peripheral VDP, % (SD) 1.3 (0.6) 3.3 (1.8)† 1.9 (0.8) 0.001
VDVPer/VDVWL, % (SD) 80 (10) 68 (13) 78 (10) 0.05
Imaging Response refers to subjects with change in ventilation-defect percent (VDP) after deep inspiration (DI) or salbutamol. No Imaging Response
refers to subjects with no VDP change after salbutamol. ND, nonresponders; IR, imaging response; NIR, imaging nonresponders; BMI, body mass index;
FEV1, forced expiratory in 1 s; %pred, percent predicted; FVC, forced vital capacity; FRC, functional residual capacity; IC, inspiratory capacity; RV,
residual volume; TLC, total lung capacity; DLCO, diffusing capacity of carbon monoxide; Raw, airways resistance; CPET, cardiopulmonary exercise test;
VO2max, maximal oxygen capacity; RER, respiratory exchange ratio at VO2max; Power, work rate; VEmax, minute ventilation at VO2max; Time to
VO2max, time taken to reach VO2max during CPET; 3He COV, ventilation coefficient of variation; VDP 	PA, change in posterior and anterior VDP;
VDP 	SI, change in superior and inferior VDP; VDVPer, ventilation defect volume in the periphery of the lung; VDVWL, VDV in the whole lung.
*Significance of difference (P  0.05) determined using multivariate ANOVA; †post hoc analysis conducted using Holm-Bonferroni, demonstrating significant
difference between groups.
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were significantly related to VDP, and Raw%pred was
not.
DISCUSSION
To understand better the determinants and physiological
consequences of ventilation defects in older never-smokers, we
evaluated pulmonary function and CPET measurements, as
well as occupational/second-hand smoke exposure in 52 older
adults. We made a number of key observations, including: 1)
three-quarters of older never-smokers had ventilation defects,
the majority of whom showed no VDP response to either DI or
salbutamol; 2) ventilation heterogeneity and VDP were signif-
icantly greater, and FEV1/FVC was significantly lower (P 
0.05) for subjects with ventilation defects responsive to DI/
salbutamol compared with subjects without ventilation defects
and subjects with ventilation defects with no response to
DI/salbutamol; and 3) in a multivariate model, FEV1, IC, and
Raw explained nearly 50% of the variability in 3He VDP in
these older never-smokers.
Ventilation abnormalities in older never-smokers. In the 39
subjects with visually obvious ventilation defects, VDP was
modest and lower than previously reported in COPD and
asthma subjects; furthermore, only four subjects showed a
change in VDP in response to DI. This is consistent with
previous findings that showed that the bronchodilatory effects
of DI decrease with age (39), which may explain the low
number of DI responders in this study. Similar to previous
observations in COPD (26) and asthma (6, 40), two subjects
showed an imaging response to salbutamol, and this supports
previous findings that reversible airflow limitation may be
underappreciated in the elderly. Unexpectedly, the majority of
older never-smokers with visually obvious ventilation defects
(n  33 of 39, 85%) did not respond to DI or salbutamol. This
is consistent with the notion that in older never-smokers, small
ventilation defects are related to irreversible airway narrowing
or collapse, loss of elastic recoil, and/or small peripheral
regions that are slow filling.
The majority of defects was observed along the periphery of
the lung, suggesting that terminal airway closure or narrowing
may be a normal, age-related pulmonary finding. Relative
peripheral VDP, 3He COV, VDP 	PA, and VDP PA gradient
were significantly greater in the imaging responders compared
with the nonresponder and no-defect groups. Together, these
findings suggest that subjects who responded to DI or salbu-
tamol also had greater ventilation heterogeneity (or patchiness)
and greater posterior/peripheral ventilation defects. The differ-
ence in ventilation heterogeneity among groups may reflect
differences in lung-filling related to airway lumen morphology,
but this is yet to be determined. Other potential mechanisms for
ventilation heterogeneity have been suggested, including the
Fig. 2. 3He MRI for 4 representative sub-
jects. 3He MRI ventilation (in blue) coregis-
tered with anatomical 1H MRI (gray-scale)
of the center coronal slice. Subject 64 (S64)
is a 69-yr-old man [forced expiratory vol-
ume in 1 s (FEV1)  130%, FEV1/forced
vital capacity (FVC)  78%, slice number
shown: 7]. S19 is a 67-yr-old man (FEV1 
131%, FEV1/FVC  75%, slice number
shown: 8). S20 is a 78-yr-old man (FEV1 
101%, FEV1/FVC  68%, slice number
shown: 9). S15 is a 65-yr-old woman (FEV1 
91%, FEV1/FVC 81%, slice number shown:
8). Yellow arrows identify the position of ven-
tilation defects. DI, deep inspiration.
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loss of parenchymal tethering forces due to alveolar collapse
that alters airway diameters, differences in regional lung ex-
pansion due to diaphragm and ribcage motions, or gravity-
dependent differences in lung expansion contributing to airway
constriction in the gravity-dependent regions (46). Neverthe-
less, in these older never-smokers, there appears to be a small,
yet irreversible, VDP component. Finally, as might be ex-
pected based on the BOLD study (28), eight subjects showed
spirometry evidence of COPD, and another 10 subjects exhib-
ited 0.70  FEV1/FVC  0.73 [0.73 accounts for FEV1 and
FVC variability of 2–3% (20, 29)]. Therefore, here, the pro-
portion of subjects with undiagnosed airflow limitation was
35%, which is in agreement with the results of the BOLD study
(28). It is interesting to note that when the eight subjects with
spirometry evidence of COPD were removed from the analy-
sis, FEV1/FVC was no longer different across the three sub-
groups; however, VDP remained different. For five subjects
with a FEV1 response to salbutamol  200 ml, there were no
significant changes in VDP, 3He COV, or any of the ventilation
clusters (C2–C5) post-salbutamol. The discrepancy between the
FEV1 response and 3He MRI response may have been due to
the effort-dependence of spirometry. It is also important to note
that all ventilation defects were peripherally located near the
distal airways, and this may also explain why salbutamol did
not influence the size or magnitude of these ventilation defects.
Relationships: ventilation defects with exercise capacity and
dyspnea. In this study, the range of dyspnea scores and mag-
nitude of ventilation defects observed were small compared
with recent findings in COPD and asthmatic subjects (6, 26, 27,
40). For these reasons, we were not surprised that there were no
differences in CPET or dyspnea measurements between sub-
jects with and without ventilation defects. Further supporting
this finding, O’Donnell and colleagues (13) have shown that it
is possible to have substantial ventilatory impairment during
exercise without a corresponding effect on dyspnea. This is
consistent with the notion that in healthy subjects, cardiovas-
cular, and not respiratory factors provide the dominant contri-
butions to exercise limitation (7, 15). Furthermore, unlike
previous work (35), there were no relationships between dys-
pnea and other pulmonary function or CPET measurements
that could be due to the limited range of dyspnea scores
reported. Subjects with ventilation defects had normal lung
function and exercise-capacity measurements for their age (4,
9, 35).
Relationships: ventilation defects with pulmonary function
and volumes. There were significant but weak univariate rela-
tionships for VDP with FEV1%pred, IC%pred, and Raw%pred,
although the relationship between VDP and Raw%pred was
dominated by three subjects with relatively large VDP values
(S3, S17, and S21). S21 had occupational and environmental
exposures, and both S3 and S17 had spirometry evidence of
GOLD II COPD. In a multivariate regression model, IC%pred,
Raw%pred, and FEV1%pred all provided significant contribu-
tions to VDP, with FEV1%pred as the strongest predictor. The
negative correlation of IC%pred with VDP is concordant with
previous results in COPD ex-smokers, who showed that ab-
Fig. 3. Scatter plots of MRI metrics. Plots showing all MRI
metrics for 3 subgroups (nonimaging responders, imaging re-
sponders, and no defects). A: VDP and relative peripheral VDP,
(B) VDP 	PA and VDP 	SI, (C) PA and SI gradients, and (D)
3He coefficient of variation (COV). Error bars are the SD of the
mean.
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normal IC is a marker of expiratory flow limitation and a
predictor of dynamic hyperinflation during exercise (31). An
increase in dynamic hyperinflation results in an increased
elastic load on the inspiratory muscles, thus increasing the
work and cost of breathing. This mechanical constraint can
predispose individuals to fatigue, and it has been shown that
dynamic hyperinflation contributes to perceived exertional dys-
pnea in subjects with COPD (31, 32, 34). It is also interesting
to note that resting IC can predict the peak, symptom-limited
VO2 in patients with expiratory flow limitation at rest (34).
Limitations. We recognize a number of limitations that
restrict the general applicability of our results. First, subjects
were classified by viewing the gray-scale images, while the
patients were still in the scanner. Offline, once the ventilation
images were coregistered to the anatomical 1H images, in two
cases, previously classified ventilation defects could be directly
related to anatomical bony structures and were unlikely to be
ventilation abnormalities. As a result, two subjects, who were
classified at the scanner as having ventilation defects, did not
appear to have these once a full analysis was completed,
although both completed DI and salbutamol inhalation. One
Table 3. Subject listing for FEV1, VDP, and 3He COV for all subjects administered salbutamol, n  35
Pre-Salbutamol Post-Salbutamol
Subject Age, yr FEV1, liter FEV1%pred VDP, % 3He COV FEV1, liter FEV1%pred VDP, % 3He COV 	FEV1, liter 	FEV1%pred 	VDP, %
001 74 1.68 89 1.35 0.20 1.70 91 0.84 0.20 0.02 2 0.51
002* 68 2.52 101 2.34 0.21 2.72 109 1.65 0.20 0.20 8 0.69
003 76 1.30 70 9.17 0.27 1.34 72 8.15 0.28 0.04 2 1.02
004 69 3.33 94 4.49 0.24 3.31 94 4.02 0.24 0.02 0 0.47
005 77 3.36 133 1.32 0.20 3.06 122 1.55 0.21 0.30 11 0.23
006 66 3.30 88 2.87 0.23 3.29 88 2.73 0.22 0.01 0 0.14
007 65 2.01 86 1.43 0.20 2.08 89 2.11 0.22 0.07 3 0.68
012 71 2.78 84 3.76 0.23 2.66 81 2.87 0.23 0.12 3 0.90
015 65 2.38 91 2.61 0.20 2.52 96 2.29 0.21 0.14 5 0.33
016 67 3.80 120 2.22 0.21 3.88 123 1.65 0.22 0.08 3 0.57
017† 69 1.24 59 10.6 0.29 1.35 64 7.91 0.27 0.11 5 2.70
018 61 3.06 111 5.26 0.22 3.14 114 5.62 0.24 0.08 3 0.36
020† 78 2.76 101 7.49 0.24 3.02 110 3.47 0.24 0.26 9 4.02
021 74 2.32 82 5.65 0.26 2.41 85 3.25 0.25 0.09 3 2.40
022* 81 2.18 123 2.92 0.22 2.43 137 5.37 0.23 0.25 14 2.45
023 68 1.96 93 1.57 0.22 2.09 99 1.25 0.21 0.13 6 0.32
025* 66 3.54 95 3.01 0.23 3.78 102 2.33 0.22 0.24 7 0.68
031 71 3.14 103 2.17 0.22 3.15 103 1.93 0.22 0.01 0 0.24
032 69 2.75 106 1.79 0.22 2.82 109 1.56 0.21 0.07 3 0.24
033 80 2.86 89 4.42 0.22 2.76 86 6.13 0.23 0.10 3 1.71
036 78 2.88 106 2.73 0.21 3.06 112 1.92 0.20 0.18 6 0.81
041 71 2.19 89 3.49 0.22 2.31 94 3.38 0.22 0.12 5 0.11
044 65 2.24 95 1.79 0.19 2.14 90 1.84 0.22 0.10 5 0.05
045 77 2.44 116 1.46 0.19 2.31 109 2.02 0.21 0.13 7 0.55
046 73 2.06 102 2.35 0.22 1.90 94 2.14 0.22 0.16 8 0.21
047 63 2.52 114 2.61 0.20 2.53 116 3.09 0.20 0.01 2 0.48
052 68 2.55 122 1.83 0.20 2.63 125 1.58 0.19 0.08 3 0.25
054 65 2.42 102 2.24 0.19 2.49 105 3.33 0.20 0.07 3 1.08
056 61 3.12 108 2.10 0.21 3.19 110 1.90 0.21 0.07 2 0.20
057 78 2.23 114 1.58 0.21 2.27 116 1.29 0.21 0.04 2 0.28
059* 79 2.53 116 2.83 0.22 2.73 125 2.90 0.22 0.20 9 0.07
060 77 2.36 120 1.26 0.20 2.37 121 1.55 0.20 0.01 1 0.29
061 74 1.53 72 3.15 0.23 1.59 75 5.21 0.24 0.06 3 2.03
063* 67 2.46 72 4.00 0.23 2.94 86 3.72 0.22 0.48 14 0.28
065 69 2.57 109 1.59 0.19 2.70 114 1.79 0.20 0.13 5 0.20
Imaging responders† 74 2.0 80 9.0 0.27 2.2 87 5.7 0.26 0.2 7.0 3.4
Mean (SD), n  2 (6) (1.1) (30) (2.2) (0.04) (1.2) (33) (3.0) (0.02) (0.1) (2.8) (0.9)
FEV1 responders* 74 2.7 102 3.1 0.22 3.0 112 3.3 0.22 0.3 10.0 0.2
Mean (SD), n  5 (7) (0.5) (20) (0.5) (0.01) (0.5) (20) (1.3) (0.01) (0.1) (3.8) (1.3)
Nonresponders 71 2.5 100 2.8 0.21 2.5 101 2.7 0.22 0.00 1.0 0.04
Mean (SD) n  28 (5) (0.6) (16) (1.7) (0.02) (0.6) (15) (1.7) (0.02) (0.1) (4.4) (0.8)
Table 4. VDP and 3He COV measurements for imaging
responders
Baseline Post-DI Post-Salbutamol
Imaging responders, n  6
VDP, % (SD) 5.8 (3.8) 4.7 (2.6) 5.7 (3.1)
3He COV (SD) 0.24 (0.04) 0.24 (0.04) 0.25 (0.02)
DI responders, n  4
VDP, % (SD) 4.2 (3.5) 3.5 (2.3)
3He COV (SD) 0.23 (0.04) 0.23 (0.04)
Salbutamol responders, n  2
VDP, % (SD) 9.0 (2.2) 7.0 (1.0) 5.7 (3.1)
3He COV (SD) 0.26 (0.04) 0.25 (0.03) 0.25 (0.02)
Table 5. Univariate and multivariate relationships for 3He
MRI VDP with pulmonary function measurements
Parameters
Univariate Relationship
VDP Multivariate Model VDP
r2 (P value) , r2, 	r2 (P value)
FEV1%pred 0.29 (0.001) 0.541, 0.292, 0.292 (0.001)
Raw%pred 0.29 (0.001) 0.359, 0.391, 0.099 (0.001)
IC%pred 0.17 (0.003) 0.265, 0.449, 0.058 (0.001)
FEV1/FVC, % 0.17 (0.002) 0.147, 0.449, 0 (0.23)
FVC%pred 0.24 (0.002) 0.114, 0.449, 0 (0.68)
RV/TLC, % 0.15 (0.005) 0.105, 0.449, 0 (0.44)
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subject had ventilation defects that responded to DI (but not
salbutamol), whereas the other subject had no ventilation
defects and did not respond to DI or salbutamol. We did not
remove these subjects from the analysis, and their inclusion did
not alter the final overall results. It should also be noted that
since all subjects were imaged 30 min after completion of
CPET, ventilation defects and ventilation heterogeneity may
have been influenced by exercise. Previous studies have shown
that during exercise, athletes experience ventilation-perfusion
mismatch and diffusion limitation (18). Other studies have
evaluated the progression of ventilation-perfusion mismatch
after exercise and showed that some subjects do not recover
fully from ventilation-perfusion mismatch until 20 min postex-
ercise (38). Because of the time delay between imaging and
CPET and the fact that in this study, VDP did not correlate
with any CPET measurements, it is unlikely that prior exercise
influenced the presence or absence of 3He MRI ventilation
defects.
Conclusions. In summary, we evaluated hyperpolarized 3He
MRI ventilation defects—a surrogate measurement of airway
function—in the first large imaging study of healthy, older
never-smokers with no history of chronic heart or lung disease.
Whereas a minority of subjects reported occupational expo-
sures, most subjects had visually obvious ventilation defects
that did not change after DI or salbutamol administration,
suggesting that terminal airway closure or narrowing may be a
normal, age-related lung finding. Whereas there were no dif-
ferences in CPET or conventional pulmonary function mea-
surements between subjects with and without ventilation de-
fects, FEV1%pred, in combination with IC%pred and Raw%pred,
predicted VDP in a multivariate regression model. Taken
together, these findings provide a better understanding of the
nature of ventilation defects in healthy, older never-smokers.
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